CHMP var af den opfattelse, at benefit/ risk- forholdet var gunstigt for følgende indikation: “ Behandling af osteoporose hos mænd med forhøjet risiko for brud.
The CHMP considered that the benefit/ risk ratio was considered to be favourable in the following indication: “ Treatment of osteoporosis in men at increased risk of fracture.